{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:00:19Z","timestamp":1767178819786,"version":"build-2238731810"},"update-to":[{"DOI":"10.1371\/journal.pntd.0005934","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,10,6]],"date-time":"2017-10-06T00:00:00Z","timestamp":1507248000000}}],"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T00:00:00Z","timestamp":1506384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1037660"],"award-info":[{"award-number":["OPP1037660"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0005934","type":"journal-article","created":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T13:24:28Z","timestamp":1506432268000},"page":"e0005934","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis"],"prefix":"10.1371","volume":"11","author":[{"given":"Randee J.","family":"Kastner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Sicuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Matwale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambrose","family":"Onapa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Tediosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,9,26]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra064142","article-title":"Control of neglected tropical diseases","volume":"357","author":"PJ Hotez","year":"2007","journal-title":"The New England journal of medicine"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1471-2334-11-172","article-title":"Ecological factors associated with dengue fever in a Central Highlands province, Vietnam","volume":"11","author":"HV Pham","year":"2011","journal-title":"BMC infectious diseases"},{"key":"ref3","unstructured":"World Health Organization. Sustaining the drive to overcome the global impact of neglected tropical diseases. summary. 2013."},{"key":"ref4","unstructured":"Imperial College London. Schistosomiasis Control Initiative: What are Neglected Tropical Diseases (NTDs). <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www3.imperial.ac.uk\/schisto\/whatwedo\/whatarentds\" xlink:type=\"simple\">http:\/\/www3.imperial.ac.uk\/schisto\/whatwedo\/whatarentds<\/ext-link>."},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1468-0262.2004.00481.x","article-title":"Worms: Identifying Impacts on Education and Health in the Presence of Treatment Externalities","volume":"72","author":"E Miguel","year":"2004","journal-title":"Econometrica"},{"key":"ref6","unstructured":"World Health Organization. Lymphatic Filariasis. 2012;Fact Sheet(102)."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0065-308X(05)61010-X","article-title":"Lymphatic filariasis: Treatment, control and elimination","volume":"61","author":"EA Ottesen","year":"2006","journal-title":"Adv Parasitol"},{"issue":"9859","key":"ref8","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"CJ Murray","year":"2012","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40249-015-0068-7","article-title":"The burden of mental health in lymphatic filariasis","volume":"4","author":"TG Ton","year":"2015","journal-title":"Infectious diseases of poverty"},{"issue":"6","key":"ref10","first-page":"935","article-title":"On the inefficiency of transmission of Wuchereria bancrofti from mosquito to human host","volume":"38","author":"NG Hairston","year":"1968","journal-title":"Bulletin of the World Health Organization"},{"issue":"RR-16","key":"ref11","first-page":"1","article-title":"Recommendations of the International Task Force for Disease Eradication","volume":"42","year":"1993","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"ref12","first-page":"259","article-title":"Zoonotic implications of cats and dogs in filarial transmission in Peninsular Malaysia","volume":"32","author":"JW Mak","year":"1980","journal-title":"Trop Geogr Med"},{"key":"ref13","unstructured":"Preventive Chemotherapy Databank Lymphatic Filariasis [Internet]. WHO. 2015 [cited 2015 January 20]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/neglected_diseases\/preventive_chemotherapy\/lf\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/neglected_diseases\/preventive_chemotherapy\/lf\/en\/<\/ext-link>."},{"key":"ref14","article-title":"Disease Control Priorities in Developing Countries","author":"DT Jamison","year":"2006"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"e2446","DOI":"10.1371\/journal.pntd.0002446","article-title":"Developing eradication investment cases for onchocerciasis, lymphatic filariasis, and human African trypanosomiasis: rationale and main challenges","volume":"7","author":"F Tediosi","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"ref16","article-title":"Disease Control Priorities in Developing Countries","author":"M Miller","year":"2006"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2105\/AJPH.2014.302454","article-title":"Investing in justice: ethics, evidence, and the eradication investment cases for lymphatic filariasis and onchocerciasis","volume":"105","author":"TC Bailey","year":"2015","journal-title":"Am J Public Health"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Walker DG, Lupp J. Guide for preparing an eradication investment case. 2011.","DOI":"10.7551\/mitpress\/9780262016735.003.0011"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"e0004147","DOI":"10.1371\/journal.pntd.0004147","article-title":"What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs","volume":"9","author":"RJ Kastner","year":"2015","journal-title":"PLoS Neglected Tropical Diseases"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1017\/S0950268899003702","article-title":"EPIFIL: the development of an age-structured model for describing the transmission dynamics and control of lymphatic filariasis","volume":"124","author":"RA Norman","year":"2000","journal-title":"Epidemiology and infection"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hec.1363","article-title":"The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches","volume":"18","author":"FM Clement Nee Shrive","year":"2009","journal-title":"Health Econ"},{"key":"ref22","unstructured":"CHOosing Interventions that are Cost Effective (WHO-CHOICE) [Internet]. World Health Organization."},{"key":"ref23","unstructured":"WHO. African Programme for Onchocerciasis Control (APOC)30 July 2015. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/blindness\/partnerships\/APOC\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/blindness\/partnerships\/APOC\/en\/<\/ext-link>."},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4269\/ajtmh.1998.58.461","article-title":"Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis","volume":"58","author":"M Boussinesq","year":"1998","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0169-4758(96)40006-0","article-title":"Severe adverse reaction risks during mass treatment with ivermectin in loiasis-endemic areas","volume":"12","author":"JP Chippaux","year":"1996","journal-title":"Parasitol Today"},{"issue":"9070","key":"ref26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","article-title":"Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection","volume":"350","author":"J Gardon","year":"1997","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12889-015-1590-z","article-title":"Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994\u20132010","volume":"15","author":"P Bhoomiboonchoo","year":"2015","journal-title":"BMC public health"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"e1210","DOI":"10.1371\/journal.pntd.0001210","article-title":"The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA)","volume":"5","author":"HG Zoure","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"ref29","first-page":"17","article-title":"The Little Green Data Book","year":"2015"},{"key":"ref30","unstructured":"Price level ratio of PPP conversion factor (GDP) to market exchange rate [Internet]. 2014."},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","article-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"F Drummond","year":"2005"},{"key":"ref32","unstructured":"Philip E Coyne DWB. The Mectizan (ivermectin) donation program for river blindness as a paradigm for pharmaceutical industry donation programs31 January 2015. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/medicinedocs\/documents\/s17517en\/s17517en.pdf\" xlink:type=\"simple\">http:\/\/apps.who.int\/medicinedocs\/documents\/s17517en\/s17517en.pdf<\/ext-link>"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1046\/j.1365-3156.1996.d01-82.x","article-title":"Cost and cost effectiveness of mass diethylcarbamazine chemotherapy for the control of bancroftian filariasis: comparison of four strategies in Tanzania","volume":"1","author":"E Michael","year":"1996","journal-title":"Trop Med Int Health"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1371\/journal.pntd.0000067","article-title":"National mass drug administration costs for lymphatic filariasis elimination","volume":"1","author":"AS Goldman","year":"2007","journal-title":"PLoS Negl Trop Dis"},{"key":"ref35","unstructured":"World Bank World Development Indicators Online [Internet]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/publications.worldbank.org\/WDI\/\" xlink:type=\"simple\">http:\/\/publications.worldbank.org\/WDI\/<\/ext-link>."},{"issue":"31","key":"ref36","first-page":"39","article-title":"Community selection of ivermectin distributors","volume":"12","author":"U Amazigo","year":"1999","journal-title":"Community Eye Health"},{"key":"ref37","unstructured":"McFarland D. Study of Cost Per Treatment with Ivermectin using the CDTI Strategy. 2005."},{"key":"ref38","article-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2003"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.actatropica.2014.03.017","article-title":"Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: a systematic review","volume":"135","author":"J Keating","year":"2014","journal-title":"Acta Trop"},{"issue":"5","key":"ref40","first-page":"431","article-title":"Who benefits from global certification of polio eradication?","volume":"120","author":"TJ John","year":"2004","journal-title":"Indian J Med Res"},{"key":"ref41","unstructured":"Global Polio Eradication Initiative. Funding update. Annual expenditures and forecasts 1988\u201320082007. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.polioeradication.org\/content\/general\/FRR_07Jan_AnnualExpenditure.pdf\" xlink:type=\"simple\">http:\/\/www.polioeradication.org\/content\/general\/FRR_07Jan_AnnualExpenditure.pdf<\/ext-link>."},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-3305-1-3","article-title":"The history of African trypanosomiasis","volume":"1","author":"D Steverding","year":"2008","journal-title":"Parasit Vectors"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"e1000412","DOI":"10.1371\/journal.pmed.1000412","article-title":"Some lessons for the future from the Global Malaria Eradication Programme (1955\u20131969)","volume":"8","author":"JA Najera","year":"2011","journal-title":"PLoS Med"},{"key":"ref44","unstructured":"Tiben DDHaDER. Q&amp;A on the historic Guinea worm eradication campaign. The Carter Center."},{"issue":"10","key":"ref45","doi-asserted-by":"crossref","first-page":"e0004147","DOI":"10.1371\/journal.pntd.0004147","article-title":"What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs","volume":"9","author":"RJ Kastner","year":"2015","journal-title":"PLoS neglected tropical diseases"},{"issue":"2","key":"ref46","doi-asserted-by":"crossref","first-page":"e0005097","DOI":"10.1371\/journal.pntd.0005097","article-title":"Costs of Transmission Assessment Surveys to Provide Evidence for the Elimination of Lymphatic Filariasis","volume":"11","author":"MA Brady","year":"2017","journal-title":"PLoS neglected tropical diseases"},{"issue":"2","key":"ref47","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/ije\/dym062","article-title":"Decision Modelling for Health Economic Evaluation","volume":"36","author":"D Caldwell","year":"2007","journal-title":"Int J Epidemiol"},{"issue":"4","key":"ref48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/hpm.900","article-title":"The impact of integrating the elimination programme for lymphatic filariasis into primary health care in the Dominican Republic","volume":"22","author":"MC Baker","year":"2007","journal-title":"Int J Health Plann Manage"},{"issue":"9710","key":"ref49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0140-6736(09)61458-6","article-title":"Mapping, monitoring, and surveillance of neglected tropical diseases: towards a policy framework","volume":"375","author":"MC Baker","year":"2010","journal-title":"Lancet"},{"issue":"9983","key":"ref50","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(15)61022-4","article-title":"Onchocerciasis and lymphatic filariasis elimination in Africa: it&apos;s about time","volume":"385","author":"DS Evans","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"ref51","doi-asserted-by":"crossref","first-page":"e3393","DOI":"10.1371\/journal.pntd.0003393","article-title":"How Effective is Integrated Vector Management Against Malaria and Lymphatic Filariasis Where the Diseases Are Transmitted by the Same Vector?","volume":"8","author":"CM Stone","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"ref52","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.2105\/AJPH.2014.301995","article-title":"A public health achievement under adversity: the eradication of poliomyelitis from Peru, 1991","volume":"104","author":"D Sobti","year":"2014","journal-title":"Am J Public Health"},{"issue":"3","key":"ref53","doi-asserted-by":"crossref","first-page":"e0003669","DOI":"10.1371\/journal.pntd.0003669","article-title":"Cessation of mass drug administration for lymphatic filariasis in Zanzibar in 2006: was transmission interrupted?","volume":"9","author":"MP Rebollo","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1146\/annurev.ento.54.110807.090626","article-title":"Role of vector control in the global program to eliminate lymphatic filariasis","volume":"54","author":"MJ Bockarie","year":"2009","journal-title":"Annu Rev Entomol"},{"issue":"8","key":"ref55","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1179\/2047773211Y.0000000010","article-title":"Cost-effectiveness of triple drug administration (TDA) with praziquantel, ivermectin and albendazole for the prevention of neglected tropical diseases in Nigeria","volume":"105","author":"D Evans","year":"2011","journal-title":"Ann Trop Med Parasitol"},{"issue":"5","key":"ref56","doi-asserted-by":"crossref","first-page":"568","DOI":"10.4269\/ajtmh.2003.68.568","article-title":"Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000","volume":"68","author":"SI McLaughlin","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"ref57","unstructured":"Damian G R R. Guidelines for Preparing an Eradication Investment Case. Disease Eradication in the 21st Century: Implications for Global Health. Cambridge, MA: Str\u00fcngmann Forum Report. p. 149\u201356."},{"issue":"6","key":"ref58","doi-asserted-by":"crossref","first-page":"e708","DOI":"10.1371\/journal.pntd.0000708","article-title":"The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000\u20132007)","volume":"4","author":"BK Chu","year":"2010","journal-title":"PLoS Negl Trop Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0005934","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,10,6]],"date-time":"2017-10-06T00:00:00Z","timestamp":1507248000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0005934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:06:18Z","timestamp":1719461178000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0005934"}},"subtitle":[],"editor":[{"given":"Sara","family":"Lustigman","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,26]]},"references-count":58,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0005934","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,26]]}}}